Skip to main content

Advertisement

Table 1 Demographic and baseline characteristics of patients

From: Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3)

Characteristic Secukinumab 300 mg (N = 139) Secukinumab 150 mg (N = 138) Placebo (N = 137)
Age (years), mean (SD) 49.3 (12.9) 50.1 (11.7) 50.1 (12.6)
Male, n (%) 67 (48.2) 61 (44.2) 59 (43.1)
Race, n (%)
 White 130 (93.5) 129 (93.5) 133 (97.1)
 American Indian or Alaska Native 0 2 (1.4) 0
 Asian 3 (2.2) 2 (1.4) 4 (2.9)
 Other 6 (4.3) 5 (3.6) 0
Weight (kg), mean (SD) 87.1 (19.4) 87.1 (20.0) 82.6 (18.5)
Number of previous anti-TNF treatments for PsA, n (%)
 0 95 (68.3) 94 (68.1) 93 (67.9)
 1 19 (13.7) 22 (15.9) 20 (14.6)
  ≥ 2 25 (18.0) 22 (15.9) 24 (17.5)
Time since diagnosis of PsA (years), mean (SD) 8.3 (9.2) 7.7 (8.5) 6.6 (6.9)
MTX use at randomization, n (%) 70 (50.4) 59 (42.8) 68 (49.6)
Systemic glucocorticoid use at randomization, n (%) 23 (16.5) 24 (17.4) 32 (23.4)
Anti-TNF-naïve, n (%) 95 (68.3) 94 (68.1) 93 (67.9)
Patients with specific disease characteristics, n (%)
 Psoriasis ≥ 3% of BSA 62 (44.6) 68 (49.3) 59 (43.1)
 Presence of dactylitis 46 (33.1) 36 (26.1) 36 (26.3)
 Presence of enthesitis 88 (63.3) 95 (68.8) 98 (71.5)
Disease and quality-of-life scores, mean (SD)
 TJC (78 joints) 19.7 (14.8) 23.3 (18.1) 21.9 (16.2)
 SJC (76 joints) 8.9 (6.4) 11.2 (9.2) 10.3 (8.6)
 DAS28-CRP 4.5 (1.0) 4.6 (1.1) 4.7 (1.1)
 PASIa 10.1 (8.6) 8.8 (6.4) 10.4 (9.0)
 Physician’s global assessment (VAS) 51.8 (19.7) 55.2 (16.7) 54.8 (18.1)
 HAQ-DI 1.1 (0.7) 1.2 (0.6) 1.2 (0.6)
 PsA pain (VAS) 54.8 (23.8) 54.4 (21.4) 53.3 (23.8)
 Patient’s global assessment (VAS) 59.9 (20.8) 59.8 (22.1) 60.6 (20.9)
 SF-36 PCS 39.2 (8.4) 37.9 (7.6) 37.4 (8.5)
  1. BSA body surface area, DAS28-CRP 28-joint Disease Activity Score using C-reactive protein, HAQ-DI Health Assessment Questionnaire—Disability Index, MTX methotrexate, N number of randomized patients, PASI Psoriasis Area and Severity Index, PsA psoriatic arthritis, SD standard deviation, SF-36 PCS Short Form-36 Physical Component Summary, SJC swollen joint count, TJC tender joint count, TNF tumor necrosis factor, VAS visual analog scale
  2. aAssessed in patients with psoriasis on at least 3% of their BSA